Q-omics provides the consensus-scored BCL6B profile across patient tissues and cancer cell-line models. BCL6B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BCL6B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, BCL6B RNA expression shows 19,599 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where BCL6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL6B survival associations across molecular data types. BCL6B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL6B RNA expression–survival associations across cancer types. High BCL6B expression shows unfavorable associations in KIRP, MESO, UVM and LUSC, but favorable associations in KIRC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for BCL6B RNA expression.
This table summarizes BCL6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BCL6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL6B shows lower tumor expression in KIRP, LUAD, KICH and LUSC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher BCL6B RNA expression in tumor versus normal tissue (log2 FC = +1.471, t-test p < 0.001).
This table shows molecular features associated with BCL6B in patient tissues and cancer cell lines. In patient samples, BCL6B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
